RxDoctor Payments Data

Mark Aziz, MD

Interventional Cardiology · Kingsport, TNNPI 1407003403

Payments from drug & device makers

$8,545in general payments, 2019–2025

Across 212 payments — averaging $40.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Edwards Lifesciences$3K
  • Abbott$977
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$389
  • E.r. Squibb & Sons, L.L.C.$234
  • Abiomed$222
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$3,43740%
  • Food & beverage$5,10860%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,545 in reported general payments places this provider in the 45th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$166,666
Medicare patients
688
Services billed
1,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$152,409
BrilintaTicagrelor44$22,482
EntrestoSacubitril/Valsartan27$17,445
Ranolazine ErRanolazine19$5,361
Metoprolol Succinate113$869
ClopidogrelClopidogrel Bisulfate152$859
Isosorbide Mononitrate ErIsosorbide Mononitrate65$745
Metoprolol Tartrate89$562
Carvedilol77$531
Amlodipine Besylate163$525
Bumetanide16$454
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$424
Rosuvastatin Calcium53$423
Atorvastatin Calcium60$361
Furosemide105$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$152,409177 claims
AstraZenecaBrilinta$24$22,48244 claims
NovartisEntresto$202$17,44527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →